Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled date : 2021 - 06 - 16 save search
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
TARS | $32.405 -1.36% -1.37% 630K
|
Health Technology
|
| O: 0.23%
H: 1.5%
C: 0.71%
disease phase 1 vaccine trial phase 3 phase 2
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.45%
H: 2.21%
C: -0.76%
disease alzheimer phase 2 results topline antibody alzheimer’s alzheimer's disease alzheimer's
CNDAP Partners with Takeda to Develop New Therapies for Alzheimer's Disease and Related Brain Disorders
Published: 2021-06-16 (Crawled : 19:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.29%
H: 0.0%
C: -0.53%
disease alzheimer therapy alzheimer’s alzheimer's disease alzheimer's train
Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2030, Foresees DelveInsight
Published: 2021-06-16 (Crawled : 18:00) - prnewswire.com
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 0.16%
H: 1.21%
C: -0.12%
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.61%
H: 18.52%
C: 16.1%
disease alzheimer growth set alzheimer’s alzheimer's disease alzheimer's
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
Published: 2021-06-16 (Crawled : 16:00) - biospace.com/
MIRM | News | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: -0.22%
H: 2.67%
C: 0.28%
disease liver disease liver rare
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
Published: 2021-06-16 (Crawled : 15:15) - biospace.com/
KKR | $92.62 -0.78% 0.0% 4.5M
|
Finance
|
| O: 0.66%
H: 1.75%
C: 1.73%
disease alzheimer fda fda approval research approval alzheimer’s alzheimer's disease alzheimer's
DTx Pharma to Participate in the 2021 BMO BioPharma Day: Spotlight on Rare Disease and Ophthalmology
Published: 2021-06-16 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 0.37%
C: -1.24%
disease biopharma rare pharma
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -4.93%
disease phase 1 trial phase 3 phase 2
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
Published: 2021-06-16 (Crawled : 12:00) - globenewswire.com
PRTK | $2.23 0.0% 4.8M
|
Health Technology
|
| O: -1.47%
H: 0.84%
C: -10.81%
disease phase 2 phase 2b
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor EventFurther signs of recovery in the core rare disease business
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
CNTG | $0.463 0.43% 0.43% 79K
|
Commercial Services
|
| O: -0.69%
H: 2.48%
C: 0.69%
disease financial results results rare
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.